Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
As part of their agreements with CMS, the manufacturers must demonstrate how these lifestyle support programs will meet the program requirements, including encouraging healthy eating and increasing physical activity, supporting medication adherence, ensuring engagement with the program on a regular basis, and ensuring availability of this program to all patients receiving these medications, either online or offline for those who have limited digital access
10.1007/s10753-021-01615-8 Inflammation
GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI eventsparticularly women
Martin Whyte, Associate Professor of Metabolic Medicine, University of Surrey This article is republished from The Conversation under a Creative Commons license
Liraglutide also showed clinically meaningful weight loss in a large randomized trial [3]